Creating Value Through Breakthrough Science

CEDAR PARK, TX – VUV Analytics, Inc., a global leader in vacuum ultraviolet (VUV) spectroscopy, welcomes Lou Cheng to the VUV team, focusing on International Business Development. After graduating from university in Delft, The Netherlands, and working briefly in R&D, Lou has been involved in laboratory equipment in the petrochemical

Novadip Biosciences, a late-stage clinical biotechnology company specializing in regenerative medicine, has announced the five-year follow-up results from the Phase 1/2 clinical trial of its investigational tissue regeneration product, NVD003, in adult patients with severe bone non-union (BNU) of the lower limb, following trauma. The five-year safety and efficacy data

VUV Analytics, Inc., a global leader in vacuum ultraviolet (VUV) spectroscopy, is excited to introduce HYDRA, a breakthrough detector for Liquid Chromatography (LC). HYDRA makes advanced chemical analysis easier with universal detection, exceptional spectral selectivity, and seamless integration into lab workflows. “HYDRA is a major step forward for Liquid Chromatography

Novadip Biosciences, a late-stage clinical biotechnology company specializing in regenerative medicine, has announced the appointment of Soumya Chandramouli as Chief Financial Officer (CFO). Soumya Chandramouli has 25 years’ experience in financial management, most recently as Chief Financial Officer of IBA Group, a listed company in the medical device and healthcare

San José Connection Partners, a consortium including Plenary Americas, Webcor/Obayashi, and HNTB, and Glydways has announced that the San José City Council voted unanimously to move the Diridon–Airport Connector into Phase 2a of project development. The decision marks a significant step toward achieving the City’s sustainable mobility goals, reflecting strong

NorthSea Therapeutics B.V. (‘NST’, or the ‘Company’), a private, late-stage clinical biotechnology company developing novel strategies to treat metabolic, cholestatic, and fibrotic diseases, has announced that results from the Phase 2b ICONA clinical trial of icosabutate in biopsy-confirmed F1-F3 metabolic dysfunction-associated steatohepatitis (MASH) were published in the Journal of Hepatology.

Ventyx Biosciences, Inc. (Nasdaq: VTYX) (“Ventyx”, “Company”), a clinical-stage biopharmaceutical company focused on developing innovative oral therapies for patients with autoimmune, inflammatory, and neurodegenerative diseases, has announced that data from the Phase 2 trial of its TYK2 inhibitor VTX958 in Crohn’s disease will be presented during the 20th Congress of

Ventyx Biosciences, Inc. (Nasdaq: VTYX) (“Ventyx”, “Company”), a clinical-stage biopharmaceutical company focused on developing innovative oral therapies for patients with autoimmune, inflammatory, and neurodegenerative diseases, has highlighted its 2025 pipeline strategy and provided clinical updates on its NLRP3 inhibitor portfolio, including VTX2735 and VTX3232. “We believe that 2025 will be

Phase Four, a leader in advanced in-space propulsion design and manufacturing, has announced the first close of its Series C funding round, securing nearly 60% of the target raise with strong participation from new and existing investors. The round is led by Artemis Group Capital, the Oklahoma-based investment firm helmed

VORAGO Technologies, a leading provider of radiation hardened and radiation tolerant MCUs and MPUs for Aerospace and Defense, and Collabora, a leader in open source software and support, today announced they are partnering to advance the use of open source to achieve resilience for mission critical applications in space. “As

Novadip Biosciences, a clinical stage biotechnology company specializing in regenerative medicine, has announced approval from the US Food and Drug Administration (FDA) for its allogenic bone grafting material NVDX3 to enter an investigational new drug study (IND). NVDX3 is an allogenic bone grafting material forming a new class of regenerative

Sagence AI™ has emerged from stealth unveiling a groundbreaking advanced analog in-memory compute architecture that directly addresses the untenable power/performance/price and environmental sustainability conundrum facing AI inferencing. Driven by its industry-first architectural innovations using analog technology, Sagence AI makes possible multiple orders of magnitude improvement in energy efficiency and cost

Novadip Biosciences, a clinical stage biotechnology company specializing in regenerative medicine, has announced positive interim results from its first-in-human clinical trial, NVDX3-CLN01, assessing the safety and efficacy of NVDX3 to heal distal radius fractures in adults. Originating from Novadip’s 3M3 platform, NVDX3 is an allogeneic bone grafting material created from human

Phase Four, a leading provider of next-generation electric propulsion (EP) solutions for satellites, has announced the planned commercialization of their monopropellant multimode capability.  Using their Maxwell Block III, Phase Four meets electric propulsion performance for a variety of mission profiles, using either ASCENT or hydrazine chemical propellants. Phase Four anticipates

Ventyx Biosciences, Inc. (Nasdaq: VTYX) (“Ventyx”), a clinical-stage biopharmaceutical company focused on advancing novel oral therapies that address a broad range of inflammatory diseases with significant unmet medical need, has announced that a late-breaking abstract including new long-term extension (LTE) data from the Phase 2 trial of tamuzimod in ulcerative

Achronix Semiconductor Corporation, a leader in FPGA-based hardware accelerator devices and high-performance eFPGA IP, has announced the availability and shipment of AC7t800 FPGA, designed to address the rapidly growing needs of data-centric applications such as generative AI, DPUs and SmartNICs. With samples available today and units already shipped to customers,

Ventyx Biosciences, Inc. (Nasdaq: VTYX) (“Ventyx”), a clinical-stage biopharmaceutical company focused on advancing novel oral therapies that address a broad range of inflammatory diseases with significant unmet medical need, has announced that Sanofi has agreed to make a $27 million strategic investment in the Company at an as-converted price of

PlanetiQ, a leading innovator of global atmospheric observing systems, has been awarded a Delivery Order (DO-4) contract valued at over $6.5M to supply the National Oceanic and Atmospheric Administration (NOAA) with their proprietary radio occultation (RO) data for a period of one year beginning September 18, 2024. “In addition to

Ventyx Biosciences, Inc. (Nasdaq: VTYX) (“Ventyx”), a clinical-stage biopharmaceutical company focused on advancing novel oral therapies that address a broad range of inflammatory diseases with significant unmet medical need, has announced that the first patient has been dosed in a Phase 2a trial of VTX3232 in patients with early Parkinson’s

Vascular Therapies, a biotechnology company focused on improving vascular access outcomes in patients with kidney disease, has announced completion of enrollment in the ACCESS 2 trial, a Phase III prospective randomized, multicenter clinical study of Sirogen™ for the surgical creation of arteriovenous (AV) fistula in patients requiring hemodialysis vascular access.